Abstract. Cancer driver genes are commonly mutationally disrupted in cancer, which confers a growth advantage to tumor cells. Recent studies preferentially search for recurrently mutated driver genes across multiple tumor samples, leading to the neglect of low-frequency mutated cancer genes. The present study was conducted to identify cancer-driving genes in thyroid cancer with two distinct tools, OncodriveFM and Dendrix, which aim to detect neglected driver genes with low mutation frequency. A total of 23,620 somatic mutations generated by whole-exome sequencing of 446 tumor/normal pairs of thyroid cancer were obtained from TCGA. Variant classification was conducted with Ensembl Variant Effect Predictor (VEP). OncodriveFM and Dendrix were applied to detect driver genes and pathways with statistical evidence. In addition, we analyzed DNA-methylation status, copy number variation, expression levels and fusion genes among these driver candidates. In total, non-synonymous mutations accounted for over 55% (13,091/23,620) of the total variants; 53 and 3 driver genes were determined by OncodriveFM and Dendrix, respectively, including 6 recurrently mutated driver genes, such as BRAF, NRAS, HRAS, EIF1AX, KRAS and 47 new genes. A total of 75 pathways with high function impact bias were identified by OncodriveFM. Two genes, FHOD3 and SRP72, were hypomethylated, overexpressed and involved in major deletions in thyroid cancer. Moreover, we identified 91 pairs of fusion genes, 89 of which were new fusion pairs in thyroid cancer. In conclusion, we successfully identified a list of new cancer genes, pathways and fusion genes, providing better insight into the tumorigenesis of thyroid cancer.
Introduction
Over the past decade, the incidence rate of thyroid cancer has greatly increased (1) . Thyroid cancer can be histologically classified into many subtypes, including follicular, anaplastic, medullary and papillary thyroid cancer (PTC), among which PTC is the most prevalent. PTCs usually have a good survival and prognosis with a 5-year survival rate higher than 95% (2); however, these cancers occasionally become aggressive and deadly through dedifferentiation into other subtypes, such as dedifferentiated thyroid cancer. Current treatments include surgery, thyroid hormone and radioactive iodine (RAI) therapy.
Identification of cancer-driving genes has been consistently a hotspot in cancer genomic research, and to date, 547 cancer genes are annotated in the COSMIC database (3) . The common approach to detect driver searches for genes that are significantly mutated in a cohort of cancer samples as compared to the background mutation rate, is through MutSigCV (4) and MuSiC (5) . Application of MutSig to 496 paired tumor/normal samples has found many over-mutated cancer drivers in thyroid cancer, such as BRAF, NRAS, HRAS, EIF1AX and KRAS (6) . However, new evidence shows that many driver genes may occur at a low frequency; for example, some cancer drivers are mutated in a small fraction (e.g., <1%) of tumors (7) . Therefore, current tools may overlook potential drivers that are mutated at a low frequency in the cancer genome, and methods that could identify these low-frequency mutated driver genes are urgently needed. Methods such as OncodriveFM (8) tend to detect genes that have bias toward the accumulation of variants with high functional impact measured by SIFT (9), PolyPhen2 (10) and MutationAssessor (11) . Another new method Dendrix based on mutual exclusivity was developed to find sets of genes in which the majority of cancer samples have at least one mutation, while display a mutation in one of the genes (12) . These prediction tools complementary to existing methods provide new opportunities to identify cancer genes that drive tumor formation and progression.
In the present study, we describe the analysis of somatic mutations detected by whole exome sequencing of 446 normal/tumor pairs of thyroid cancer samples from the Cancer Genome Atlas (TCGA) database, OncodriveFM and Dendrix were applied to prioritize cancer driver genes and pathways. We identified 53 cancer driver candidates and 75 pathways with significant bias of functional impact. In addition, we analyzed DNA methylation status, copy number variation, expression levels and fusion genes among these driver candidates. We found that two genes, FHOD3 and SRP72, were hypomethylated, overexpressed and involved in major deletions, suggesting that they play an oncogenic role in thyroid cancer. Our study highlights the importance of identifying low-frequency mutated cancer-driving genes in an integrated way.
Materials and methods

Prediction of the functional effect of cancer mutations, genes and pathways.
A total of 23,620 somatic mutations detected by whole-exome sequencing of 446 tumor/normal pairs were obtained from TCGA (http://cancergenome.nih.gov/, download on July 14, 2015) . Functional impact of somatic mutations in the coding genome was classified with Ensembl Variant Effect Predictor (VEP) (13) . Cancer genes and pathways were predicted by OncodriveFM (8) and Dendrix (12) programs and all the parameters were set to default. Genes and pathways with Q-value <0.05 were regarded as cancer gene and pathway candidates. GO enrichment analysis was performed for all of the driver candidates from the home page of the GOC website (14) (http://geneontology.org/).
DNA methylation, RNA-seq data processing and expression analyses. DNA methylation data for 389 thyroid cancer samples were obtained from TCGA, and the undefined value was replaced with an average β value. The average β value was computed for each gene and cancer sample. RNA-seq data of 18 papillary thyroid carcinoma biopsies and 4 normal thyroid tissues were obtained from the study of Costa et al (GSE64912) (15) . Read alignment with human genome 19 was conducted with TopHat2 (16), and read count was computed with bedtools v2.22.1 (17) for each gene. Differentially expressed genes were determined with DEseq2 (18) package in R between tumor and normal tissues with cutoffs of a false discovery rate (FDR) ≤0.5 and absolute fold-change ≥2.
Sources of copy number variation and fusion gene data.
We obtained copy number variations of 501 thyroid cancer samples which were detected by SNP array and publically available at the Broad Institute (6) (gdac.broadinstitute.org). RNA-seq data from the study of Costa et al was aligned to the human genome with Tophat2, fusion genes were detected with TopHat-Fusion (16) , and all of the parameters were set by default.
Statistical analysis. Data are presented as mean, and differences between different groups were drawn with the Wilcoxon rank sum test in R. P<0.05 was considered to indicate a statistically significant difference and the null hypothesis was rejected.
Results
Catalogue of somatic mutations.
A total of 23,620 somatic mutations detected by whole-exome sequencing of 446 thyroid cancer specimens were obtained from TCGA. Among these, 23,070 were single-nucleotide variants (SNVs), 550 were small insertions or deletions. C>T/G>A, C>A/G>T and T>C/A>G accounted for 32.10, 21.04 and 19.21% of the variant types in the non-CpG sites, and 4.42, 1.65 and 1.35% of variant types in the CpG islands. C>T/G>A, C>A/G>T and T>C/A>G were the three predominant transitions in thyroid cancer (Fig. 1A) . A total of 12,817, 274 and 5 single nucleotide variations were classified as missense, nonsense and nonstop mutations, respectively by VEP. A total of 7,988 single nucleotide variations were classified as silent. A total of 318 and 103 small deletions and insertions introduced translational frameshifts, and 72 and 8 small deletions and insertions were in frame mutations. A total of 448 and 22 mutations were located in splicing sites and translation start sites, while non-synonymous mutations accounted for >55% (13,091/23,620) of the total variants (Fig. 1B) . Thyroid cancer showed a significantly lower non-synonymous mutation density (0.31 non-synonymous mutations per Mb per sample, on average) as compared to other cancers, such as melanoma and lung cancer (4, 19) .
Cancer driver genes and pathways in thyroid cancer. We applied OncodriveFM to identify driver genes in thyroid cancer. In total, 53 genes were determined as driver candidates by OncodriveFM. Among them, BRAF, NRAS, HRAS, KRAS, PPM1D and EIF1AX are known recurrently mutated driver genes in thyroid cancer, with mutation frequencies of 59.64, 8.52, 3.59, 1.12, 1.35 and 1.35% across all samples (6) . However, most of the driver candidates were not frequently mutated in thyroid cancer ( Fig. 2A and B) . The P53 signaling genes were also determined as driver genes; TP53, ATM and CHEK2, showed relatively low mutation frequencies (<2.5% in all cases), suggesting the inactivation of the P53 signaling pathway in thyroid cancer. Several known cancer genes of other cancer types were first identified as drivers in thyroid cancer, such as BRCA1 in breast cancer (20) , MLL and MLL3 in hepatocellular carcinoma (HCC) (21) and gastric cancer (22) , ATM in glioma (23) and leukemia (24) , PTPN11 in acute myeloid leukemia (25) as well as DICER1 in pleuropulmonary blastoma (26) . In addition, we also identified many new driver candidates, for example, mitogen-activated protein kinase kinase kinase 3 (MEKK3) and Transport and Golgi organisation protein 1 (TANGO). MEKK3 is elevated in esophageal squamous cell carcinoma (ESCC), and overexpression of MEKK3 indicates poor prognosis of ESCC (27) . Breast and ovarian cancers show an elevated MEKK3 protein level and increased NF-κB binding activity, and overexpression of MEKK3 was found to activate NF-κB binding activity and upregulate cell survival and anti-apoptotic genes such as Bcl-2 and XIAP in U373 cells, which enhanced cellular resistance to apoptosis induced by chemotherapeutic agents (28) . Another driver candidate, MIA3, also known as TANGO, is a member of the melanoma inhibitory activity (MIA) gene family. It displays a tumor-suppressor function in multiple cancer types, such as human colon and hepatocellular carcinoma (29) and melanoma (30) .
Dendrix was developed to identify sets of genes which are mutated in a large fraction of cancer samples and whose mutations are mutually exclusive. We next analyzed somatic mutations of thyroid cancer with Dendrix. In total, 10,839 genes were reported as mutated in at least one patient. We performed Dendrix for sets with sizes ranging from 2 to 5. When k=2, the pair BRAF and NRAS was sampled 96.1% of the time. When k=3, the triplet (BRAF, NRAS and KRAS) was sampled with a frequency of 22.2%. For k=4, no gene set had sample frequency >1%. The pair (BRAF, NRAS) and triplet (BRAF, NRAS and KRAS) were the most prevalent gene sets in the mutual exclusivity test, further supporting the importance of BRAF, NRAS and KRAS in the tumorigenesis of thyroid cancer.
We analyzed the enrichment of GO terms of the 53 cancer gene candidates, and 27 GO terms were determined with significant statistical evidence ( Table I ). The majority of GO terms were cancer-associated, such as apoptotic signaling pathway, regulation of protein metabolic process and cell cycle and DNA damage checkpoint. These findings further support that the driver candidates identified by OncodriveFM and Dendrix have critical functions in thyroid cancer. OncodriveFM also revealed 75 pathways with high FM bias in thyroid cancer, such as regulation of actin cytoskeleton, melanoma, thyroid cancer, renal cell carcinoma, bladder cancer, non-small cell lung cancer (NSCLC), alcoholism, endometrial cancer, prostate cancer, glioma, chronic myeloid leukemia and acute myeloid leukemia (Table II) .
DNA methylation in thyroid cancer. Epigenetic alterations such as methylation of cytosine-guanine dinucleotides (CpG) play an important role in human carcinogenesis. We obtained DNA methylation data from TCGA and analyzed its association with driver genes in thyroid cancer. First of all, we used hierarchical clustering to analyze DNA methylation profiling and found two clusters of hypermethylated and hypomethylated genes (Fig. 3A) . This suggested that genes with hypermethylation or hypomethylation on promoters are associated with tumor suppressors or oncogenes (31) . We selected the top 500 hypermethylated and hypomethylated genes which had the highest or lowest mean β value, respectively, and analyzed functional enrichment with GO terms.
Hypomethylated genes were significantly enriched in 80 GO terms. Among them, many were found to be associated with cell cycle regulation, metabolic process, cell division and gene expression, while, hypermethylated genes were enriched in only in 9 GO terms, such as detection of stimulus, G-protein coupled receptor signaling pathway and sensory perception of smell. In addition, we obtained RNA-seq data of 18 papillary thyroid carcinoma biopsies and 4 normal thyroid tissues from the study of Costa et al (15) . We analyzed the expression levels of hypermethylated and hypomethylated genes. The hypermethylated genes were found to be significantly lower expressed as compared to the hypomethylated ones (RPKM, 3.08 vs. 4.72, P<2.2e-16; Wilcoxon rank sum test) (Fig. 3B) . Among all the driver candidates, CD163, USP6, R3HDM1, DNAH1, ARHGAP5 and R3HDM1 showed hypermethylation, while PPM1D, SRP72, GNPAT and TDG exhibited hypomethylation (Fig. 3C ), suggesting they may be involved in tumorigenesis of thyroid cancer by altering the methylation status. We also identified 504 differentially expressed genes between thyroid cancer and normal tissues (Fig. 4A) . Among them, four were driver gene candidates, including AIM1, FHOD3, SRP72 and FRG1B (Fig. 4B) . AIM1, SRP72 and FRG1B are overexpressed and hypomethylated, which suggests they may have oncogenic function in thyroid cancer. 
2).
Fusion genes in thyroid cancer. We obtained RNA-seq data of 18 papillary thyroid carcinoma samples from the study of Costa et al (15) , and applied Tophat-Fusion to detect potential fusion genes in thyroid cancer. In total, we found 91 pairs of fusion genes in 18 cancer samples (Fig. 6A) . C7orf50-LOC101927021, ATG7-VGLL4, RP11-131L23.1-ZNHIT6, MRPS28-TPD52 and SLC28A3-FRMD3 were among the most frequent fusion pairs in thyorid cancer, with a frequency of 94.44, 88.89, 88.89, 77.78 and 77.78% in the cancer samples (Fig. 6B) . We compared our list of fusion gene pairs with known fusion genes of thyroid cancer from TCGA Fusion Gene Data Portal (http://54.84.12.177/PanCanFusV2/). There were only two known fusion gene pairs, ANK3-RET (33.33%) and PPARG-PAX8 (5.56%), while the majority of pairs of fusion genes were newly identified. In addition, we found that three fusion genes were differentially expressed between the thyroid cancer and normal tissues, including NTM, SLC7A7 and RXRG. The three genes were all overexpressed in thyroid cancer, with a fusion frequency: NTM-OPCML (16.67%), RXRG-POU2F1 (5.56%) and SLC7A7-TRAJ24 (5.56%) ( Fig. 6C and D) . Finally, no driver candidate was found to be implicated in fusion genes, indicating that gene fusion may not be the primary mechanism for the involvement of driver genes in thyroid cancer.
Discussion
In the present study, we carried out a full analysis on the somatic mutations generated by whole exome sequencing of thyroid cancer samples. We found 53 cancer gene candidates and 75 cancer pathways. Among them, BRAF, NRAS, HRAS, EIF1AX, CHEK2 and PPM1D are recurrently mutated (6) . BRAF as a proto-oncogene regulates the MAP kinase/ERK signaling pathway, which affects cell division, differentiation and secretion. Mutations within BRAF contribute to carcinogenesis of a variety of cancer types, such as thyroid cancer (32) and melanoma (33) . KRAS, HRAS and NRAS are the most common oncogenes from the RAS gene family. They encode proteins of the GTPase superfamily which plays a great role in signal transduction, protein biosynthesis, cell division, translocation of proteins and transport of vesicles. Mutations in RAS proteins are associated with ~30% of all human cancers (34). PPM1D is a member of the PP2C family which is known to be a negative regulator of cell stress response pathways. It has been reported to be involved in multiple human tumors, such as lung cancer (35), breast cancer and ovarian cancer (36) . However, the majority of driver candidates were new cancer genes with low mutation frequency. A great advantage of OncodriveFM and Dendrix is that these two tools identify genes and pathways which accumulate variants of high function impact or mutationally exclusive, independent of the cancer mutation frequency. Therefore, application of these tools in cancer research enables us to better explore cancer-driving genes and pathways in the cancer genome. In addition, we also identified many drivers that were differentially expressed, hypermethylated, hypomethylated and CNV-associated, such as SRP72 and FRG1B, suggesting that these genes may contribute to the formation and progression of thyroid cancer in various ways. We found 91 pairs of fusion genes using RNA-seq data. Three of them, NTM, SLC7A7 and RXRG fusion genes, were overexpressed in thyroid cancer; however, their fusion partners were not affected. These fusion genes are actively implicated in various cancer types, for instance, RXRG is a member of the Retinoid X receptors. It shows tumor-suppressor function in NSCLC (37) and colon cancer (38) . RXRG upregulation is associated with dedifferentiation, advanced tumor stage and metastasis (39) and increased apoptosis (40) in thyroid cancer. POU class 2 homeobox 1 (POU2F1), also known as OCT1, is a ubiquitous member of the POU transcription factor family. POU2F1 shows pro-proliferative and pro-apoptotic activity in bladder carcinoma (41) . Neurotrimin (NTM) and OPCML are members of the IgLON family of immunoglobulin (Ig) domain-containing glycosylphosphatidylinositol (GPI)-anchored cell adhesion molecules. OPCML as a tumor-suppressor gene is commonly inactivated by either allele loss or DNA methylation in epithelial ovarian cancer (42) . SLC7A7 is overexpressed in glioblastoma (GBM), and its overexpression indicates a poor outcome of GBM (43) . Genetic variants in SLC7A7 are associated with the risk of glioma (44) . Therefore, pairs of these fusion genes may play an important role in the carcinogenesis of thyroid cancer.
In conclusion, taken together, we successfully found a set of cancer-related genes, pathways and fusion genes in thyroid cancer. The findings provide new insight into the pathogenesis of thyroid cancer, therefore paving a potential avenue by which to cure thyroid cancer, based on the disruption of driver genes, pathways and fusion gene pairs.
